BLTE
Belite Bio, Inc
Price Chart
Latest Quote
$145.72
+2.37 (+1.65%)
Current Price
| Previous Close | $143.35 |
| Open | $143.00 |
| Day High | $147.00 |
| Day Low | $142.80 |
| Volume | 138,128 |
Stock Information
| Shares Outstanding | 40.27M |
| Net Income | $-102.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.87B |
| EPS (TTM) | $-2.74 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Income | $-102.36M |
| Book/sh | $19.29 |
| Employees | 41 |
Financial Ratios
| Current Ratio | 33.56 |
Returns & Margins
| ROA | -15.65% |
| ROE | -22.10% |
Ownership
| Insider Ownership | 43.65% |
| Institutional Ownership | 24.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 64.48 |
| P/B | 7.56 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $228.89 |
Technical Indicators
| SMA20 | $153.52 |
| SMA50 | $162.26 |
| SMA200 | $160.42 |
| RSI | 40.09 |
| ATR | 6.2466 |
| Shares Float | 19.55M |
| Short Float | 6.03% |
| Short Ratio | 7.77 |
| Volatility | -1.23 |
| Rel Volume | 0.85 |
Performance History
| Week | -5.65% |
| Month | -12.18% |
| Quarter | -4.41% |
| 6 Months | -8.20% |
| YTD | -8.51% |
| Year | +56.99% |
| 3 Years | +325.58% |
| 10 Years | +1276.02% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $145.72 | 138,100 |
| 2026-10-26 | $143.35 | 137,200 |
| 2026-10-23 | $147.33 | 49,900 |
| 2026-10-22 | $150.27 | 125,700 |
| 2026-10-21 | $153.18 | 113,800 |
| 2026-10-20 | $154.45 | 209,700 |
| 2026-10-19 | $147.34 | 164,400 |
| 2026-10-16 | $142.78 | 193,800 |
| 2026-10-15 | $152.62 | 195,900 |
| 2026-10-14 | $152.72 | 158,500 |
| 2026-10-13 | $151.87 | 233,400 |
| 2026-10-12 | $158.59 | 259,200 |
| 2026-10-09 | $154.49 | 179,300 |
| 2026-10-08 | $152.52 | 154,400 |
| 2026-10-07 | $156.08 | 97,800 |
| 2026-10-06 | $155.61 | 190,300 |
| 2026-10-05 | $159.18 | 133,300 |
| 2026-10-02 | $159.56 | 184,800 |
| 2026-10-01 | $162.98 | 198,800 |
| 2026-09-30 | $169.82 | 142,000 |
| 2026-09-29 | $166.66 | 186,900 |
| 2026-09-28 | $165.93 | 127,300 |
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
đ° Latest News
No news articles available at the moment. Check back later for updates on BLTE.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $2,000 | $20,000 | $25,000 | $16,000 |
| Total Expenses | $84,208,000 | $39,996,000 | $31,668,000 | $12,821,000 |
| Other Income Expense | $-41,000 | $141,000 | $-4,000 | $166,000 |
| Other Non Operating Income Expenses | $-41,000 | $141,000 | $-4,000 | $166,000 |
| Net Non Operating Interest Income Expense | $6,638,000 | $3,717,000 | $49,000 | $7,000 |
| Interest Expense Non Operating | $2,000 | $20,000 | $25,000 | $16,000 |
| Operating Expense | $84,208,000 | $39,996,000 | $31,668,000 | $12,821,000 |
| General And Administrative Expense | $38,831,000 | $10,057,000 | $6,824,000 | $3,952,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Net Interest Income | $6,638,000 | $3,717,000 | $49,000 | $7,000 |
| Interest Income | $6,640,000 | $3,737,000 | $74,000 | $23,000 |
| Normalized Income | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Net Income From Continuing And Discontinued Operation | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Total Operating Income As Reported | $-84,208,000 | $-39,996,000 | $-31,668,000 | $-12,821,000 |
| Net Income Common Stockholders | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Net Income | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Net Income Including Noncontrolling Interests | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Net Income Continuous Operations | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Pretax Income | $-77,611,000 | $-36,138,000 | $-31,623,000 | $-12,648,000 |
| Interest Income Non Operating | $6,640,000 | $3,737,000 | $74,000 | $23,000 |
| Operating Income | $-84,208,000 | $-39,996,000 | $-31,668,000 | $-12,821,000 |
| Per Share | ||||
| Diluted EPS | $-2.31 | $-1.18 | $-1.19 | $-0.63 |
| Basic EPS | $-2.31 | $-1.18 | $-1.19 | $-0.63 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-77,145,000 | $-35,669,000 | $-31,199,000 | $-12,434,000 |
| Reconciled Depreciation | $464,000 | $449,000 | $399,000 | $198,000 |
| EBITDA (Bullshit earnings) | $-77,145,000 | $-35,669,000 | $-31,199,000 | $-12,434,000 |
| EBIT | $-77,609,000 | $-36,118,000 | $-31,598,000 | $-12,632,000 |
| Diluted Average Shares | $33,538,160 | $30,538,378 | $26,593,673 | $19,976,596 |
| Basic Average Shares | $33,538,160 | $30,538,378 | $26,593,673 | $19,976,596 |
| Diluted NI Availto Com Stockholders | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Tax Provision | $0 | $6,000 | $9,000 | $0 |
| Research And Development | $45,377,000 | $29,939,000 | $24,844,000 | $8,869,000 |
| Selling General And Administration | $38,831,000 | $10,057,000 | $6,824,000 | $3,952,000 |
| Other Gand A | $38,831,000 | $10,057,000 | $6,824,000 | $3,952,000 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $765,570,000 | $141,857,000 | $87,134,000 | $41,470,000 |
| Total Assets | $780,556,000 | $152,132,000 | $94,642,000 | $44,273,000 |
| Total Non Current Assets | $286,284,000 | $5,059,000 | $4,702,000 | $1,466,000 |
| Non Current Prepaid Assets | $425,000 | $130,000 | $104,000 | $88,000 |
| Investmentin Financial Assets | $280,166,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $4,916,000 | $3,964,000 | $3,297,000 | $31,000 |
| Other Intangible Assets | $4,916,000 | $3,964,000 | $3,297,000 | $31,000 |
| Current Assets | $494,272,000 | $147,073,000 | $89,940,000 | $42,807,000 |
| Other Current Assets | $5,000 | - | - | - |
| Prepaid Assets | $1,127,000 | $1,330,000 | $916,000 | $699,000 |
| Receivables | $718,000 | $594,000 | $867,000 | $19,000 |
| Other Receivables | $66,000 | - | $818,000 | - |
| Taxes Receivable | $18,000 | $19,000 | $31,000 | $17,000 |
| Accrued Interest Receivable | $634,000 | $575,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $492,422,000 | $145,149,000 | $88,157,000 | $42,089,000 |
| Cash And Cash Equivalents | $352,932,000 | $31,677,000 | $88,157,000 | $42,089,000 |
| Cash Equivalents | $15,641,000 | $0 | - | - |
| Cash Financial | $337,291,000 | $31,677,000 | $88,157,000 | $42,089,000 |
| Other Non Current Assets | - | - | $62,000 | - |
| Non Current Deferred Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $429,000 | $537,000 | $886,000 | $866,000 |
| Long Term Debt And Capital Lease Obligation | $188,000 | $261,000 | $578,000 | $668,000 |
| Current Debt And Capital Lease Obligation | $241,000 | $276,000 | $308,000 | $198,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,070,000 | $6,311,000 | $4,211,000 | $2,772,000 |
| Total Non Current Liabilities Net Minority Interest | $188,000 | $261,000 | $578,000 | $668,000 |
| Current Liabilities | $9,882,000 | $6,050,000 | $3,633,000 | $2,104,000 |
| Other Current Liabilities | $599,000 | $289,000 | $149,000 | $74,000 |
| Payables And Accrued Expenses | $7,432,000 | $4,782,000 | $2,449,000 | $1,450,000 |
| Payables | $5,000 | $13,000 | - | - |
| Equity | ||||
| Common Stock Equity | $770,486,000 | $145,821,000 | $90,431,000 | $41,501,000 |
| Total Equity Gross Minority Interest | $770,486,000 | $145,821,000 | $90,431,000 | $41,501,000 |
| Stockholders Equity | $770,486,000 | $145,821,000 | $90,431,000 | $41,501,000 |
| Gains Losses Not Affecting Retained Earnings | $-536,000 | $-660,000 | $-374,000 | $-392,000 |
| Retained Earnings | $-185,258,000 | $-107,647,000 | $-71,503,000 | $-39,871,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Treasury Shares Number | $13,405 | $31,253 | $35,031 | - |
| Ordinary Shares Number | $39,339,960 | $31,826,549 | $29,149,444 | $24,898,908 |
| Share Issued | $39,353,365 | $31,857,802 | $29,184,475 | $24,898,908 |
| Tangible Book Value | $765,570,000 | $141,857,000 | $87,134,000 | $41,470,000 |
| Invested Capital | $770,486,000 | $145,821,000 | $90,431,000 | $41,501,000 |
| Working Capital | $484,390,000 | $141,023,000 | $86,307,000 | $40,703,000 |
| Capital Lease Obligations | $429,000 | $537,000 | $886,000 | $866,000 |
| Total Capitalization | $770,486,000 | $145,821,000 | $90,431,000 | $41,501,000 |
| Additional Paid In Capital | $956,276,000 | $254,125,000 | $162,305,000 | $81,761,000 |
| Capital Stock | $4,000 | $3,000 | $3,000 | $3,000 |
| Common Stock | $4,000 | $3,000 | $3,000 | $3,000 |
| Long Term Capital Lease Obligation | $188,000 | $261,000 | $578,000 | $668,000 |
| Current Capital Lease Obligation | $241,000 | $276,000 | $308,000 | $198,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,610,000 | $703,000 | $727,000 | $382,000 |
| Current Accrued Expenses | $7,427,000 | $4,769,000 | $2,449,000 | $1,450,000 |
| Dueto Related Parties Current | $5,000 | $13,000 | $0 | $0 |
| Investments And Advances | $280,166,000 | $0 | - | - |
| Held To Maturity Securities | $280,166,000 | $0 | - | - |
| Net PPE | $777,000 | $965,000 | $1,301,000 | $1,347,000 |
| Accumulated Depreciation | $-507,000 | $-341,000 | $-183,000 | $-91,000 |
| Gross PPE | $1,284,000 | $1,306,000 | $1,484,000 | $1,438,000 |
| Leases | $187,000 | $187,000 | $187,000 | $187,000 |
| Other Properties | $1,022,000 | $1,044,000 | $1,233,000 | $1,228,000 |
| Machinery Furniture Equipment | $75,000 | $75,000 | $64,000 | $23,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $139,490,000 | $113,472,000 | $0 | - |
| Duefrom Related Parties Current | - | $0 | $18,000 | $2,000 |
| Construction In Progress | - | - | - | $31,000 |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-37,166,000 | $-29,385,000 | $-29,900,000 | $-11,852,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-36,988,000 | $-29,234,000 | $-29,837,000 | $-11,458,000 |
| Cash Flow From Continuing Operating Activities | $-36,988,000 | $-29,234,000 | $-29,837,000 | $-11,458,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-178,000 | $-151,000 | $-63,000 | $-394,000 |
| Investing Cash Flow | $-305,107,000 | $-110,572,000 | $-63,000 | $-394,000 |
| Cash Flow From Continuing Investing Activities | $-305,107,000 | $-110,572,000 | $-63,000 | $-394,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $182,021,000 | $42,236,000 | $55,188,000 | $37,990,000 |
| Financing Cash Flow | $663,233,000 | $83,595,000 | $75,959,000 | $36,963,000 |
| Cash Flow From Continuing Financing Activities | $663,233,000 | $83,595,000 | $75,959,000 | $36,963,000 |
| Net Other Financing Charges | $370,374,000 | $-368,000 | $-1,230,000 | $-1,030,000 |
| Net Common Stock Issuance | $182,021,000 | $42,236,000 | $55,188,000 | $37,990,000 |
| Common Stock Issuance | $182,021,000 | $42,236,000 | $55,188,000 | $37,990,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $1,000 | $0 | $0 | $16,000 |
| Income Tax Paid Supplemental Data | $0 | $6,000 | $9,000 | $0 |
| End Cash Position | $352,932,000 | $31,677,000 | $88,157,000 | $42,089,000 |
| Beginning Cash Position | $31,677,000 | $88,157,000 | $42,089,000 | $17,344,000 |
| Effect Of Exchange Rate Changes | $117,000 | $-269,000 | $9,000 | $-366,000 |
| Changes In Cash | $321,138,000 | $-56,211,000 | $46,059,000 | $25,111,000 |
| Proceeds From Stock Option Exercised | $110,838,000 | $41,727,000 | $22,001,000 | $3,000 |
| Net Investment Purchase And Sale | $-304,929,000 | $-110,421,000 | $0 | $0 |
| Sale Of Investment | $147,065,000 | $77,844,000 | $0 | $0 |
| Purchase Of Investment | $-451,994,000 | $-188,265,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-35,000 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-35,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-178,000 | $-116,000 | $-63,000 | $-394,000 |
| Purchase Of PPE | $-178,000 | $-116,000 | $-63,000 | $-394,000 |
| Change In Working Capital | $2,553,000 | $1,133,000 | $-2,427,000 | $-491,000 |
| Change In Other Current Liabilities | $-301,000 | $-305,000 | $-244,000 | $-71,000 |
| Change In Payables And Accrued Expense | $3,838,000 | $2,476,000 | $1,421,000 | $332,000 |
| Change In Accrued Expense | $3,846,000 | $2,463,000 | $1,421,000 | $373,000 |
| Change In Payable | $-8,000 | $13,000 | - | $-41,000 |
| Change In Prepaid Assets | $-918,000 | $-1,112,000 | $-3,532,000 | $-720,000 |
| Change In Receivables | $-66,000 | $74,000 | $-72,000 | $-32,000 |
| Other Non Cash Items | $-1,313,000 | $-3,610,000 | - | - |
| Stock Based Compensation | $38,919,000 | $8,987,000 | $3,823,000 | $1,483,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-49,000 | $0 | $0 |
| Depreciation Amortization Depletion | $464,000 | $449,000 | $399,000 | $198,000 |
| Depreciation And Amortization | $464,000 | $449,000 | $399,000 | $198,000 |
| Amortization Cash Flow | $12,000 | $4,000 | $0 | $0 |
| Amortization Of Intangibles | $12,000 | $4,000 | $0 | $0 |
| Depreciation | $452,000 | $445,000 | $399,000 | $198,000 |
| Net Income From Continuing Operations | $-77,611,000 | $-36,144,000 | $-31,632,000 | $-12,648,000 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-10-25